Key result
β-blocker therapy at discharge was not significantly associated with reduced 2-year all-cause mortality in ACS patients with LVEF ≥40% undergoing PCI (HR 0.762; 95% CI 0.36-1.64; P=0.485).
Why the study?
The clinical impact of beta-blockers in patients with adequate LVEF who underwent PCI for ACS was not well defined.
Does beta-blocker therapy at discharge reduce all-cause mortality in ACS patients with LVEF ≥40% who underwent PCI?
Population
5,631 ACS patients who underwent PCI discharged with LVEF ≥40%
Comparison
Beta-blocker prescription at discharge vs without beta-blockers
Design
Prospective cohort study
Follow-up
2 years
Authors
Loading...
Should not yet change practice in ACS with LVEF ≥40% after PCI; leaves open a hypothesis-generating 1-year signal in unstable angina.
Cohort (n=5,631)
Does beta-blocker therapy at discharge reduce all-cause mortality in ACS patients with LVEF ≥40% who underwent PCI?
Hazard Ratio: 0.762 (95% CI 0.36–1.64)
Absolute Event Rate: 0.9% vs 1.4%
p-value: p=0.485
Beta-blocker therapy at discharge does not improve 2-year survival in the overall population of ACS patients with preserved LVEF undergoing PCI, but may offer a temporary mortality benefit in those with unstable angina.
Chen et al. (2020) conducted a cohort in Acute Coronary Syndrome without Heart Failure (n=5,631). β-blocker therapy at discharge vs. without β-blocker use at discharge was evaluated on all-cause mortality (HR 0.762, 95% CI 0.36 to 1.64, p=0.485). β-blocker therapy at discharge was not significantly associated with reduced 2-year all-cause mortality in ACS patients with LVEF ≥40% undergoing PCI (HR 0.762; 95% CI 0.36-1.64; P=0.485).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: